GlaxoSmithKline has announced that they would be applying their chronic Obstructive Pulmonary Disease (COPD) drug "Relovair" for regulatory approval by the mid of 2012. They are expecting to launch the medicine in Europe as well, but for the purpose of asthma.

Anglo-American drugs giant GlaxoSmithKline said clinical trial has given them an assurance that their drug would be a great hit in the multibillion-dollar market of lung medicines.

Glaxo and its US partner Theravance revealed that they are almost done with their phase-three trials, and would soon be done with another trial which aims to provide Relovair as a onetime inhaler for asthma patients.

The COPD trial included 1,620 patients and continued for 52 weeks. It was found that Relovair has performed better than its competitor Vilanterol every time. Then also the company said they would look to it that there are no side effects of the drug.

After this news got publicized that Glaxo would be applying for regulatory approval, the shares of the drugmaker to climb by 21%. Theravance CEO Rick Winningham said, "We are very excited with the new data and GSK's plan to submit regulatory applications for Relovair in the U. S. and Europe this year".

He further affirmed that details of both the drugs trials would be presented at an international conference soon. Further informing about Relovair, Winningham, said it is an inhaler which needs to be taken once a day.

This means once you have taken it in the morning then you are free from the tension to not to repeat it. It is only such medicine for COPD and asthma patients which would be meant to be taken once a day. So, once they are done with other trivial issues, they would apply for regulatory approval.